Adults as young as 18 can now receive the immunization.The logo of the British multinational pharmaceutical company GlaxoSmithKline on top of its headquarters in London on Feb. 2, 2022. Justin Tallis/AFP via Getty Images3/13/2026|Updated: 3/13/2026U.S. regulators have expanded the approval for GlaxoSmithKline’s vaccine against respiratory syncytial virus (RSV), the company said March 13.Adults as young as 18 can now receive the vaccine, provided they are at increased risk of lower respiratory tract disease caused by RSV because of having conditions such as chronic liver disease or compromised immune systems.
-1
C
Ottawa
Friday, March 13, 2026
The Alliance Press is the world leader in online chained news and information and seeks to inform, engage and empower the world. We expose the information that wasn't known before or current events broadcast over the radio, television, online or in print media. Our content is now available through your mobile phone. No matter where your on-the-go lifestyle takes you, TAP brings the news directly to you.
More from CN
Contact
© The Alliance Media Group design by CODEUS